抗PD-1免疫治疗可诱导肾小管上皮PD-L1表达增高的间质性肾炎
该研究对15例接受抗PD-1治疗并发生急性肾损伤需肾活检的患者进行形态学与免疫组化分析,其中9例为急性间质性肾炎(AIN),6例为急性肾小管坏死(ATN)。肾小管上皮细胞膜PD-L1染色仅见于抗PD-1相关AIN,而不见于抗PD-1相关ATN、其他药物性AIN或狼疮肾炎。提示PD-L1免疫组化有助于鉴别抗PD-1相关AIN与其他AIN。
要点
- 抗PD-1相关AIN中肾小管上皮细胞膜PD-L1表达阳性,而其他原因AIN阴性。
- PD-L1免疫组化可作为鉴别抗PD-1相关AIN与其他AIN的辅助工具。
- 抗PD-1治疗患者发生AKI时需肾活检明确AIN与ATN。
核心结论
- 肾小管上皮细胞膜PD-L1免疫组化染色仅见于抗PD-1治疗相关AIN,可用于与其他AIN鉴别。
研究设计与样本
- 回顾性分析15例接受抗PD-1治疗并发生急性肾损伤需肾活检患者的标本,行PD-1和PD-L1免疫组化染色。
- 对照包括9例未接受抗PD-1药物的AIN活检标本和9例狼疮肾炎伴活动性间质炎症标本。
主要发现
- 15例中9例为AIN,6例为无AIN的急性肾小管坏死(ATN)。
- 所有AIN和狼疮肾炎患者T细胞PD-1染色均弱。
- 肾小管上皮细胞膜PD-L1染色仅见于抗PD-1相关AIN,不见于抗PD-1相关ATN、其他药物性AIN或狼疮肾炎。
临床怎么用
- 对接受抗PD-1治疗并发生AKI的患者,肾活检行PD-L1免疫组化有助于鉴别AIN与其他原因肾损伤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Novel anticancer therapies include anti-programmed cell death protein-1 (PD-1) and anti-programmed death ligand-1 (PD-L1) drugs. These novel medications have side effects in different organs, including the kidney. The most common adverse effect in the kidney is acute interstitial nephritis (AIN). No diagnostic criteria are available to distinguish AIN associated with anti-PD-1 therapy from other AINs. METHODS: Kidney biopsy specimens from patients on anti-PD-1 therapy were stained with antibodies to PD-1 and PD-L1. Herein we report morphologic and immunohistochemical findings in 15 patients who received anti-PD-1 therapy and developed acute kidney injury requiring a kidney biopsy. RESULTS: Among these patients, 9 had AIN and 6 had no AIN but showed acute tubular necrosis (ATN). Immunohistochemistry with antibodies to PD-1 and PD-L1 was performed on all of these biopsy specimens and on 9 randomly selected biopsy specimens with AIN from patients who did not receive anti-PD-1 medications, as well as 9 patients with lupus nephritis and active-appearing interstitial inflammation. There was weak staining for PD-1 in T cells in all patients with AIN and lupus; however, tubular epithelial cell membrane staining for PD-L1 was seen only in patients with anti-PD-1 therapy-associated AIN, and not in patients with anti-PD-1 therapy-associated ATN, and not in those with AIN secondary to other medications, or patients with lupus nephritis. CONCLUSION: We propose that immunohistochemistry with PD-L1 could be a useful tool to differentiate AIN associated with anti-PD-1 therapy from other AINs.
引用
- Cassol C, Satoskar A, Lozanski G, et al. Anti-PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1. Kidney Int Rep. 2019. PMID: 31440705. doi:10.1016/j.ekir.2019.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。